JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -0.80%396.37B | 2.04%272.19B | -4.08%122.52B | 8.77%520.34B | 8.53%399.56B | 4.78%266.75B | 4.57%127.73B | 8.33%478.39B | 9.16%368.16B | 12.53%254.59B |
Operating income | -0.80%396.37B | 2.04%272.19B | -4.08%122.52B | 8.77%520.34B | 8.53%399.56B | 4.78%266.75B | 4.57%127.73B | 8.33%478.39B | 9.16%368.16B | 12.53%254.59B |
Cost of sales | ---- | -0.59%-262.4B | ---- | -9.00%-508.32B | ---- | -5.01%-260.86B | ---- | -9.62%-466.34B | ---- | -15.05%-248.4B |
Operating expenses | 1.85%-381.95B | -0.59%-262.4B | 4.79%-118.5B | -9.00%-508.32B | -8.90%-389.16B | -5.01%-260.86B | -5.04%-124.46B | -9.62%-466.34B | -10.72%-357.37B | -15.05%-248.4B |
Gross profit | 38.67%14.42B | 66.24%9.79B | 22.85%4.02B | -0.33%12.02B | -3.66%10.4B | -4.77%5.89B | -10.70%3.27B | -25.54%12.06B | -25.58%10.79B | -40.15%6.18B |
Selling expenses | -8.88%-551.85M | -3.91%-194.04M | -6.23%-183.5M | 18.48%-358.09M | -4.84%-506.86M | -7.78%-186.74M | -25.22%-172.75M | -19.53%-439.25M | 21.59%-483.47M | -6.77%-173.25M |
Administrative expenses | -9.82%-1.72B | -4.52%-1.8B | -6.30%-553.55M | -7.09%-3.83B | 11.81%-1.57B | -2.07%-1.72B | 2.17%-520.77M | 3.81%-3.57B | 3.62%-1.78B | 1.79%-1.69B |
Research and development expenses | -38.62%-900.98M | ---- | -70.26%-272.21M | ---- | 3.44%-649.95M | ---- | 26.32%-159.88M | ---- | -9.36%-673.12M | ---- |
Profit from asset sales | -91.30%818.7K | ---- | 700.36%143.14K | ---- | -59.74%9.41M | ---- | -99.90%17.89K | ---- | -49.44%23.38M | ---- |
Revaluation surplus | -177.20%-411.53M | ---- | -125.85%-177.03M | ---- | 1,171.83%533.04M | ---- | 218.27%684.8M | ---- | 89.04%-49.73M | ---- |
-Changes in the fair value of other assets | -177.20%-411.53M | ---- | -125.85%-177.03M | ---- | 1,171.83%533.04M | ---- | 218.27%684.8M | ---- | 89.04%-49.73M | ---- |
Impairment and provision | -10.35%-293.08M | -246.43%-138.28M | -90.82%18.19M | 96.41%-10.21M | 70.06%-265.59M | 171.03%94.44M | 7.40%198.06M | 40.71%-284.59M | 35.18%-887.03M | -6.03%-132.95M |
-Other impairment is provision | -10.35%-293.08M | -246.43%-138.28M | -90.82%18.19M | 96.41%-10.21M | 70.06%-265.59M | 171.03%94.44M | 7.40%198.06M | 40.71%-284.59M | 35.18%-887.03M | -6.03%-132.95M |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -8.74%-1.13B |
Special items of operating profit | -1,242.79%-1.52B | -191.81%-1.39B | 130.69%187.86M | 58.57%3.05B | -75.33%132.93M | -18.87%1.51B | -952.94%-612.2M | 194.38%1.92B | 122.86%538.8M | 159.33%1.86B |
Operating profit | 11.75%7.73B | 12.24%6.27B | 14.59%2.67B | 12.27%10.87B | 7.41%6.92B | 13.36%5.58B | 7.53%2.33B | 27.81%9.68B | -0.48%6.44B | 18.70%4.93B |
Financing cost | -69.06%-732.09M | -4.16%-1.19B | -78.05%-498.1M | -18.13%-2.32B | -101.35%-433.04M | ---1.15B | -7.04%-279.76M | ---1.97B | 69.40%-215.07M | ---- |
Share of profits of associates | ---- | -67.91%14.94M | ---- | 152.95%97.96M | ---- | 136.22%46.57M | ---- | -29.78%-185.01M | ---- | -101.62%-128.58M |
Share of profit from joint venture company | ---- | 162.63%6.8M | ---- | 65.96%-10.33M | ---- | 29.05%-10.86M | ---- | -98.64%-30.34M | ---- | 18.89%-15.3M |
Special items of earning before tax | -144.28%-16.39M | ---- | -15.41%19.98M | ---- | 235.14%37.02M | ---- | 697.10%23.62M | ---- | 57.08%-27.39M | ---- |
Earning before tax | 7.06%6.98B | 13.90%5.1B | 5.69%2.19B | 15.12%8.63B | 5.22%6.52B | -6.43%4.48B | 9.06%2.08B | 1.10%7.5B | 8.64%6.2B | 17.58%4.78B |
Tax | -30.44%-1.53B | -29.88%-970.11M | -26.44%-392.92M | -0.09%-1.4B | -2.18%-1.17B | 18.41%-746.91M | 11.78%-310.77M | -1.12%-1.4B | -21.63%-1.15B | -17.85%-915.41M |
After-tax profit from continuing operations | 1.94%5.45B | 10.70%4.13B | 2.04%1.8B | 18.58%7.23B | 5.91%5.35B | -3.59%3.73B | 13.79%1.76B | 1.10%6.1B | 6.07%5.05B | 17.51%3.87B |
Earning after tax | 1.94%5.45B | 10.70%4.13B | 2.04%1.8B | 18.58%7.23B | 5.91%5.35B | -3.59%3.73B | 13.79%1.76B | 1.10%6.1B | 6.07%5.05B | 17.51%3.87B |
Minority profit | 15.32%470.43M | 60.74%411.47M | 806.61%85.59M | 412.67%482.31M | 25.96%407.94M | -5.68%255.98M | -87.75%9.44M | -63.38%94.08M | 26.28%323.87M | 96.78%271.39M |
Profit attributable to shareholders | 0.83%4.98B | 7.01%3.72B | -2.29%1.71B | 12.40%6.75B | 4.54%4.94B | -3.44%3.47B | 19.10%1.76B | 3.97%6B | 4.92%4.73B | 14.05%3.6B |
Basic earnings per share | 0.70%1.44 | 7.00%1.07 | -1.96%0.5 | 12.72%1.95 | 4.38%1.43 | -3.85%1 | 18.60%0.51 | 3.59%1.73 | 5.38%1.37 | 14.29%1.04 |
Diluted earnings per share | 7.00%1.07 | 12.72%1.95 | -3.85%1 | 3.59%1.73 | 14.29%1.04 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.